Can Cannabis Be Used as a Treatment for Chronic Pain?

Some cannabis-based medicines can provide small, short-term improvements in certain types of chronic pain, especially neuropathic pain. The benefit is not consistent across products or conditions, and side effects can outweigh it. Cannabis should be considered, if at all, within an individualized pain-management plan.

Understanding Chronic Pain

Chronic pain persists beyond normal healing or recurs over a prolonged period. It can involve nerve injury, musculoskeletal disease, and other causes. Assessment matters because reducing pain intensity is only one goal: mobility, sleep, daily activities, and treatment of the underlying condition also matter.

Cannabis contains many compounds. THC causes intoxication; CBD does not produce the same high. Neither description, on its own, tells you whether a product is effective for your pain.

What the Updated Evidence Shows

The 2025 AHRQ systematic review included 29 randomized trials and 15 observational studies. Some THC-containing preparations produced small improvements in pain, mainly over four weeks to less than six months. Dizziness, sedation, and nausea were more common with several of these treatments.

CBD-only oral products did not show improved pain or function compared with placebo in the reviewed evidence. Findings for specific studied preparations cannot simply be transferred to every retail oil, edible, topical, or cannabis flower. Evidence about long-term outcomes and opioid reduction remained insufficient.

Potential Benefits Should Be Measurable

If a clinician considers a trial appropriate, agree on a concrete goal before starting: for example, walking farther, completing a daily task, or sleeping with fewer pain-related awakenings. Track function as well as pain. A treatment that reduces a pain score but causes disabling dizziness may not be a useful improvement.

Do not assume that cannabis prevents opioid dependence or makes opioid withdrawal safe. Any change to an opioid prescription requires a plan with the treating clinician. Cannabis should not be used to abruptly replace prescribed pain treatment.

Risks and People Who Need Extra Caution

The American College of Physicians’ 2025 advice emphasizes counselling about benefits and harms, and advises against inhaled cannabis for chronic noncancer pain. It identifies groups for whom harms are likely to outweigh benefits, including adolescents and young adults, people with current or past substance-use disorder, people with serious mental illness, and frail patients or those at risk of falling.

Pregnancy, breastfeeding, or plans to become pregnant also require avoiding cannabis for pain management under that guidance. A clinician should review other medicines, driving requirements, and work responsibilities before any treatment decision. Retail product labels do not replace that assessment.

US Legal Status in 2026

An April 2026 federal order moved specified FDA-approved and qualifying state-licensed medical marijuana products to Schedule III. It was a targeted change, separate from broader marijuana rescheduling. State access rules and product-specific federal requirements still matter; scheduling does not establish that a product is an approved treatment for chronic pain.

Questions to Discuss With a Clinician

• What is the likely cause of my pain, and which treatments have the best evidence for it?
• What benefit would make a trial worthwhile, and when would we review it?
• Could cannabis interact with my medicines or increase falls, sedation, or mental-health risks?
• How would we stop treatment if it does not help?

Final Thoughts

Cannabis is not a universal answer to chronic pain. A limited trial may be reasonable for selected patients after a clinical discussion, but expectations should be modest and outcomes reviewed. Continue evidence-based care for the underlying condition and do not substitute a product recommendation for a pain-management plan.